---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023035"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:05:05.143632+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending

## Summary
- Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.
- Cash and cash equivalents $7.4M at June 30; proforma $17.4M after July private placement.
- Closed $10M private placement led by Nantahala Capital, with potential $16.3M from warrants tied to milestones.
- EUA for Niyad (nafamostat mesylate) submitted to FDA in April; responses awaited. Registrational study to start Q4 2023.
- DSUVIA divested to Alora in April; AcelRx receives 15% royalty on commercial sales, 75% on DoD sales, up to $116.5M milestones.

## SEC filing metadata
- accession: 0001437749-23-023035
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/0001437749-23-023035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/acrx20230809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023035
- JSON: https://secwatch.observer/filing/0001437749-23-023035.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023035.txt

## Key facts
- Earnings Releases
  TALPHERA, INC. reported the three months ended June 30, 2023 results: revenue $0.3 million, net income $4.4 million, EPS $0.40 per basic and diluted share. Guidance reaffirmed.
  - Period: the three months ended June 30, 2023
  - Revenue: $0.3 million
  - Net income: $4.4 million
  - EPS: $0.40 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Information ● The cash and cash equivalents balance was $7.4 million as of June 30, 2023. The senior debt with Oxford was fully repaid in the second quarter. ● Revenues of $0.3 million for the second quarter primarily represents the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/0001437749-23-023035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.